CD34 and myelodysplastic syndrome: Especially for this study, we obtained and used CD34+ hematopoietic stem and progenitor cells (HSPCs) from two healthy elderly controls (Ctrl1, Ctrl3) and two SF3B1 mutated MDS patients at diagnosis (MDS2, MDS4) (Additional file 1: Table S2).